A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | March 2005 |
| End Date: | January 2007 |
A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia
This study will assess the efficacy and safety of intravenous beta-lactam, in comparison
with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by
Legionella. The anticipated time on study treatment is 3-12 months and the target sample
size is 100-500 individuals.
with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by
Legionella. The anticipated time on study treatment is 3-12 months and the target sample
size is 100-500 individuals.
Inclusion Criteria:
- male or female patients at least 18 years of age;
- hospitalization with community-acquired pneumonia or development of pneumonia within
48 hours of being hospitalized for another reason;
- fever;
- new or increased productive cough;
- chest pain, shortness of breath, or rapid breathing.
Exclusion Criteria:
- requiring intubation or ventilation;
- nursing home or extended care within 60 days before study;
- concomitant bacterial infection requiring antibiotics;
- long-term immunosuppressive therapy.
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials